<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03025828</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 16-2402</org_study_id>
    <nct_id>NCT03025828</nct_id>
  </id_info>
  <brief_title>Adrenocorticotropic Hormone in Membranous Nephropathy</brief_title>
  <official_title>Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of adrenocorticotropic hormone (ACTH,&#xD;
      Acthar) on the loss of proteins in the urine (proteinuria) in patients with membranous&#xD;
      nephropathy. Acthar is a hormone that stimulates steroid production from small glands above&#xD;
      the kidneys. It has direct protective effects on the kidney and is currently approved by the&#xD;
      FDA to treat kidney disorders associated with proteins in the urine, but the mechanisms of&#xD;
      action are not entirely understood and will be studied in the present trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with membranous nephropathy and nephrotic syndrome will be treated with ACTH for 6&#xD;
      months. Proteinuria remission at 12 months will be the primary endpoint. Different biomarkers&#xD;
      including anti-PLA2R autoantibodies, circulating regulatory T cells, and autoreactive memory&#xD;
      B cells will be serially measured to identify predictors of response to therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Actual">December 16, 2020</completion_date>
  <primary_completion_date type="Actual">December 16, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of proteinuria</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Change in proteinuria at baseline versus after 12 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24h Proteinuria</measure>
    <time_frame>12 months</time_frame>
    <description>Protein concentration in the urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Glomerular Filtration Rate (GFR)</measure>
    <time_frame>12 months</time_frame>
    <description>GFR measures kidney function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PLA2R antibodies levels</measure>
    <time_frame>12 months</time_frame>
    <description>blood levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PLA2R memory B cells</measure>
    <time_frame>12 months</time_frame>
    <description>blood levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+CD25+CD127lowFoxP3+ T cell</measure>
    <time_frame>12 months</time_frame>
    <description>blood levels - one single cell subset identified by different markers</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>Acthar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acthar will be administered subcutaneously (SC) 80 units for the first week and then 80 units twice weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACTHar</intervention_name>
    <description>for 6 months</description>
    <arm_group_label>Acthar</arm_group_label>
    <other_name>ACTH</other_name>
    <other_name>Acthar Injectable Product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 70 years&#xD;
&#xD;
          -  Free of immunosuppression for at least 3 months&#xD;
&#xD;
          -  Capability of understanding the purpose of the study&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Epidermal growth factor receptor (eGFR) &lt; 30ml/min/1.73m2&#xD;
&#xD;
          -  Kidney Transplant&#xD;
&#xD;
          -  Secondary MN (defined on the basis of clinical criteria)&#xD;
&#xD;
          -  Type 1 or Type 2 diabetes mellitus (prior diagnosis of gestational diabetes mellitus&#xD;
             is not an exclusion)&#xD;
&#xD;
          -  History of previous use of Acthar for treatment of nephrotic syndrome&#xD;
&#xD;
          -  Prior sensitivity to Acthar or other porcine protein products&#xD;
&#xD;
          -  Contraindication to Acthar per Prescribing Information&#xD;
&#xD;
          -  Planned treatment with live or live attenuated vaccines once enrolled in the study&#xD;
&#xD;
          -  More than three previous treatment regiments&#xD;
&#xD;
          -  Participation to other clinical trials over the previous 12 months&#xD;
&#xD;
          -  History of cancer, except carcinoma in situ and treated basal and squamous cell&#xD;
             carcinomas&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
          -  Current substance abuse&#xD;
&#xD;
          -  Any clinically relevant condition that might affect study participation and/or study&#xD;
             results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Cravedi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2017</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Paolo Cravedi</investigator_full_name>
    <investigator_title>Assistant Professor, Nephrology</investigator_title>
  </responsible_party>
  <keyword>Membranous nephropathy</keyword>
  <keyword>adrenocorticotropic hormone</keyword>
  <keyword>ACTH</keyword>
  <keyword>proteinuria</keyword>
  <keyword>glomerulonephritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

